- Home
- TEL vs IQV Comparison
TEL vs IQV Comparison
Compare TEL & IQV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TEL | IQV |
|---|---|---|
| Founded | 1941 | 1982 |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 69.6B | 36.4B |
| IPO Year | 2007 | 2013 |
Fundamental Metrics
Financial Performance| Metric | TEL | IQV |
|---|---|---|
| Price | $227.59 | $243.43 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 11 | 15 |
| Target Price | ★ $258.00 | $236.93 |
| AVG Volume (30 Days) | ★ 1.8M | 1.2M |
| Earning Date | 01-21-2026 | 02-05-2026 |
| Dividend Yield | ★ 1.24% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | 6.16 | ★ 7.30 |
| Revenue | ★ $17,262,000,000.00 | $15,904,000,000.00 |
| Revenue This Year | $12.57 | $6.15 |
| Revenue Next Year | $7.40 | $5.39 |
| P/E Ratio | $37.29 | ★ $33.45 |
| Revenue Growth | ★ 8.94 | 3.85 |
| 52 Week Low | $116.30 | $134.65 |
| 52 Week High | $250.67 | $246.71 |
Technical Indicators
Market Signals| Indicator | TEL | IQV |
|---|---|---|
| Relative Strength Index (RSI) | 44.34 | 72.79 |
| Support Level | $221.26 | $221.78 |
| Resistance Level | $237.17 | $246.71 |
| Average True Range (ATR) | 4.53 | 4.62 |
| MACD | -0.26 | 1.91 |
| Stochastic Oscillator | 37.10 | 87.65 |
Price Performance
Historical ComparisonAbout TEL TE Connectivity Ltd. New Switzerland Registered Shares
TE Connectivity is the largest electrical connector supplier in the world, supplying interconnect and sensor solutions to the transportation, industrial, and communications markets. With operations in 150 countries and over 500,000 stock-keeping units, TE has a broad portfolio that forms the electrical architecture of its end customers' cutting-edge innovations.
About IQV IQVIA Holdings Inc.
Iqvia is the result of the 2016 merger of Quintiles, a leading global contract research organization, and IMS Health, a leading healthcare data and analytics provider. The research and development segment focuses primarily on providing outsourced late-stage clinical trials for pharmaceutical, device, and diagnostic firms. The technology and analytics segment provides aggregated information and technology services to clients in the healthcare industry, including pharmaceutical companies, providers, payers, and policymakers, as well as data and analytics capabilities for clinical trials, including virtual trials. The company also has a small contract sales business.